Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

@article{Dahan2016TherapeuticAO,
  title={Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.},
  author={Rony Dahan and Bryan C. Barnhart and Fubin Li and Aaron P. Yamniuk and Alan J Korman and Jeffrey V Ravetch},
  journal={Cancer cell},
  year={2016},
  volume={29 6},
  pages={
          820-831
        }
}
While engagement of the inhibitory Fcγ-receptor (FcγR) IIB is an absolute requirement for in vivo antitumor activity of agonistic mouse anti-CD40 monoclonal antibodies (mAbs), a similar requirement for human mAbs has been disputed. By using a mouse model humanized for its FcγRs and CD40, we revealed that FcγRIIB engagement is essential for the activity of human CD40 mAbs, while engagement of the activating FcγRIIA inhibits this activity. By engineering Fc variants with selective enhanced… CONTINUE READING
BETA

Figures and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

Mouse model recapitulating human Fcγ receptor structural and functional diversity.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2012
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcgR Engagement

Dahan
  • Cancer Cell (2016),
  • 2016

Similar Papers

Loading similar papers…